Tumor biomarkers in melanoma

Cancer Control

Volumn 16, Issue 3, 2009, Pages 219-224

  Ugurel, Selma ^a   Utikal, Jochen ^a   Becker, Jürgen C ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 100; KI 67 ANTIGEN; MELAN A; PROTEIN S 100; TUMOR MARKER;

CANCER DIAGNOSIS; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MELANOMA; PATHOGENESIS; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 67650526416     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480901600303     Document Type: Review

References (84)

1. Ohsie SJ, Sarantopoulos GP, Cochran AJ, et al. Immunohistochemical characteristics of melanoma. J Cutan Pathol. 2008;35(5):433-444.
2. Niezabitowski A, Czajecki K, Ryś J, et al. Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study. J Surg Oncol. 1999;70(3):150-160. (Pubitemid 29147163)
3. Berger AJ, Davis DW, Tellez C, et al. Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res. 2005;65(23): 11185-11192. (Pubitemid 41713390)
4. Alonso SR, Ortiz P, Pollán M, Pérez-Gómez B, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol. 2004;164(1):193-203. (Pubitemid 38364604)
5. Janku F, Novotny J, Julis I, et al. KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients. Melanoma Res. 2005;15(4):251-256. (Pubitemid 41127460)
6. Cruz J, Reis-Filho JS, Silva P, et al. Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas. Oncology. 2003;65(1):72-82. (Pubitemid 36829093)
7. Kraehn GM, Utikal J, Udart M, et al. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Br J Cancer. 2001;84(1):72-79. (Pubitemid 32102507)
8. Massoumi R, Kuphal S, Hellerbrand C, et al. Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med. 2009;206(1):221-232. Epub 2009 Jan 5.
9. Udart M, Utikal J, Krähn GM, et al. Chromosome 7 aneusomy: a marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. Neoplasia. 2001;3(3):245-254. (Pubitemid 32747573)
10. Jovanovic B, Kröckel D, Linden D, et al. Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma. J Invest Dermatol. 2008;128(11):2696-2704. Epub 2008 May 29.
11. Reschke M, Mihic-Probst D, van der Horst EH, et al. HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res. 2008; 14(16):5188-5197.
12. Polsky D, Melzer K, Hazan C, et al. HDM2 protein overexpression and prognosis in primary malignant melanoma. J Natl Cancer Inst. 2002; 94(23):1803-1806. (Pubitemid 36004356)
13. Wang Y, Dai DL, Martinka M, et al. Prognostic significance of nuclear ING3 expression in human cutaneous melanoma. Clin Cancer Res. 2007; 13(14):4111-4116.
14. Ugurel S, Houben R, Schrama D, et al. Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response. Clin Cancer Res. 2007;13(21):6344-6350. (Pubitemid 350075023)
15. Mihic-Probst D, Mnich CD, Oberholzer PA, et al. p16 expression in primary malignant melanoma is associated with prognosis and lymph node status. Int J Cancer. 2006;118(9):2262-2268.
16. Dai DL, Martinka M, Li G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol. 2005;23(7):1473-1482. (Pubitemid 46260035)
17. Roesch A, Becker B, Meyer S, et al. Overexpression and hyperphosphorylation of retinoblastoma protein in the progression of malignant melanoma. Mod Pathol. 2005;18(4):565-572. (Pubitemid 40478121)
18. Mikhail M, Velazquez E, Shapiro R, et al. PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin Cancer Res. 2005;11(14):5153-5157.
19. Flørenes VA, Maelandsmo GM, Faye R, et al. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome. J Pathol. 2001;195(5):530-536. (Pubitemid 34030789)
20. Flørenes VA, Faye RS, Maelandsmo GM, et al. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res. 2000;6(9):3614-3620. (Pubitemid 30694945)
21. Winnepenninckx V, Lazar V, Michiels S, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst. 2006;98(7):472-482.
22. Gimotty PA, Van Belle P, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005;23(31):8048-8056. (Pubitemid 46657407)
23. Ostmeier H, Fuchs B, Otto F, et al. Prognostic immunohistochemical markers of primary human melanomas. Br J Dermatol. 2001;145(2):203-209. (Pubitemid 32955343)
24. Fujimoto A, Takeuchi H, Taback B, et al. Allelic imbalance of 12q22- 23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res. 2004;64(6):2245-2250. (Pubitemid 38339479)
25. Fecker LF, Geilen CC, Tchernev G, et al. Loss of proapoptotic Bcl-2- related multidomain proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol. 2006;126(6):1366-1371. (Pubitemid 43997920)
26. Tas F, Duranyildiz D, Argon A, et al. Serum bcl-2 and survivin levels in melanoma. Melanoma Res. 2004;14(6):543-546. (Pubitemid 40221148)
27. Dadras SS, Paul T, Bertoncini J, et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol. 2003;162(6):1951-1960. (Pubitemid 36613052)
28. Wu H, Barusevicius A, Babb J, et al. Pleiotrophin expression correlates with melanocytic tumor progression and metastatic potential. J Cutan Pathol. 2005;32(2):125-130. (Pubitemid 40216048)
29. Bachmann IM, Straume O, Puntervoll HE, et al. Importance of Pcadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res. 2005;11 (24 Pt 1):8606-8614. (Pubitemid 43005907)
30. Thies A, Moll I, Berger J, et al. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol. 2002;20(10):2530-2536. (Pubitemid 34525740)
31. Nishizawa A, Nakanishi Y, Yoshimura K, et al. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients. Cancer. 2005;103(8):1693-1700. (Pubitemid 40490031)
32. Andersen K, Nesland JM, Holm R, et al. Expression of S100A4 com bined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod Pathol. 2004;17(8):990-997. (Pubitemid 38993784)
33. Saalbach A, Wetzel A, Haustein UF, et al. Interaction of human Thy- 1 (CD 90) with the integrin alphavbeta3 (CD51/CD61): an important mechanism mediating melanoma cell adhesion to activated endothelium. Oncogene. 2005;24(29):4710- 4720. (Pubitemid 41032607)
34. Redondo P, Lloret P, Idoate M, et al. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. Clin Exp Dermatol. 2005;30(5):541-545. (Pubitemid 41076024)
35. Massi D, Franchi A, Borgognoni L, et al. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol. 1999;30(3):339-344. (Pubitemid 29125155)
36. Luongo V, Pirozzi G, Caracò C, et al. HLA allele frequency and clinical outcome in Italian patients with cutaneous melanoma. Tissue Antigens. 2004;64(1):84-87. (Pubitemid 38850374)
37. Swart GW, Lunter PC, Kilsdonk JW, et al. Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration? Cancer Metastasis Rev. 2005;24(2):223-236.
38. Scala S, Ottaiano A, Ascierto PA, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res. 2005;11(5):1835-1841. (Pubitemid 40471847)
39. Duncan LM, Deeds J, Hunter J, et al. Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res. 1998;58(7):1515-1520. (Pubitemid 28193617)
40. Weinlich G, Eisendle K, Hassler E, et al. Metallothionein: overexpression as a highly significant prognostic factor in melanoma. A prospective study on 1270 patients. Br J Cancer. 2006;94:835-841.
41. Rangel J, Nosrati M, Torabian S, et al Osteopontin as a molecular prognostic marker for melanoma. Cancer. 2008;112(1):144-150.
42. Carvalho L, Lipay M, Belfort F, et al. Telomerase activity in prognostic histopathologic features of melanoma. J Plast Reconstr Aesthet Surg. 2006; 59(9):961-968. Epub 2006 Apr 3. (Pubitemid 44241803)
43. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135-2147. (Pubitemid 41653105)
44. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24(26):4340-4346. Epub 2006 Aug 14. (Pubitemid 46630793)
45. Viros A, Fridlyand J, Bauer J, et al. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med. 2008;5(6): e120. (Pubitemid 351919116)
46. Ugurel S, Schadendorf D, Pföhler C, et al. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clin Cancer Res. 2006;12(18): 5454-5463.
47. Guo HB, Stoffel-Wagner B, Bierwirth T, et al. Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer. 1995;31A(11): 1898-1902.
48. Schultz ES, Diepgen TL, Von Den Driesch P. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Br J Dermatol. 1998;138(3):426-430. (Pubitemid 28145509)
49. Hauschild A, Engel G, Brenner W, et al. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol. 1999;140(6):1065-1071. (Pubitemid 29284578)
50. Krähn G, Kaskel P, Sander S, et al. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res. 2001;21(2B):1311-1316. (Pubitemid 32494139)
51. Garbe C, Leiter U, Ellwanger U, et al. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer. 2003;97(7):1737-1745. (Pubitemid 36350717)
52. Bogdahn U, Apfel R, Hahn M, et al. Autocrine tumor cell growthinhibiting activities from human malignant melanoma. Cancer Res. 1989;49 (19): 5358-5363. (Pubitemid 19240474)
53. Blesch A, Bosserhoff AK, Apfel R, et al. Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res. 1994;54(21): 5695-5701.
54. Stahlecker J, Gauger A, Bosserhoff A, et al. MIA as a reliable tumor marker in the serum of patients with malignant melanoma. Anticancer Res. 2000;20(6D):5041-5044. (Pubitemid 32319076)
55. Agrup P, Carstam R, Wittbjer A, et al. Tyrosinase activity in serum from patients with malignant melanoma. Acta Derm Venereol. 1989;69(2): 120-124. (Pubitemid 19057350)
56. Wimmer I, Meyer JC, Seifert B, et al. Prognostic value of serum 5-Scysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Cancer Res. 1997;57(22):5073-5076. (Pubitemid 27498122)
57. Stoitchkov K, Letellier S, Garnier JP, et al. Evaluation of the serum L-dopa/L-tyrosine ratio as a melanoma marker. Melanoma Res. 2003; 13(6):587-593. (Pubitemid 38296896)
58. Ugurel S, Rappl G, Tilgen W, et al. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol. 2001;19(2):577-583. (Pubitemid 32112873)
59. Hirai S, Kageshita T, Kimura T, et al. Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression. Melanoma Res. 1997;7(1):58-62. (Pubitemid 27110283)
60. Vuoristo MS, Laine S, Huhtala H, et al. Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma. Eur J Cancer. 2001;37(13):1629-1634. (Pubitemid 32778608)
61. Franzke A, Probst-Kepper M, Buer J, et al. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer. 1998;78(1):40-45. (Pubitemid 28276767)
62. Nikkola J, Vihinen P, Vuoristo MS, et al. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res. 2005;11(14):5158-5166. (Pubitemid 41003701)
63. Yoshino Y, Kageshita T, Nakajima M, et al. Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and -2 in patients with malignant melanoma. J Dermatol. 2008;35(4):206-214. (Pubitemid 351561711)
64. Mouawad R, Benhammouda A, Rixe O, et al. Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res. 1996;2(8):1405-1409. (Pubitemid 26299441)
65. Dummer W, Becker JC, Schwaaf A, et al. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res. 1995;5(1):67-68.
66. Nemunaitis J, Fong T, Shabe P, et al. Comparison of serum interleukin- 10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest. 2001;19(3):239-247. (Pubitemid 32374364)
67. Boyano MD, Garcia-Vázquez MD, López-Michelena T, et al. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br J Cancer. 2000;83(7):847-852. (Pubitemid 30707617)
68. Rebmann V, Ugurel S, Tilgen W, et al. Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients. Int J Cancer. 2002;100(5):580-585. (Pubitemid 34816159)
69. Westhoff U, Fox C, Otto FJ. Soluble HLA class I antigens in plasma of patients with malignant melanoma. Anticancer Res. 1998;18(5B):3789-3792. (Pubitemid 28564267)
70. Sirott MN, Bajorin DF, Wong GY, et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer. 1993;72(10):3091-3098.
71. Deichmann M, Kahle B, Moser K, et al. Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer. 2004; 91(4):699-702. (Pubitemid 39141627)
72. Ugurel S, Bell N, Sucker A, et al. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma. Int J Cancer. 2005;117(5):825-830. (Pubitemid 41598835)
73. Ugurel S, Rappl G, Tilgen W, et al. Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res. 2001;7(5):1282-1286. (Pubitemid 32708681)
74. Schmidt H, Johansen JS, Sjoegren P, et al. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol. 2006;24(5):798-804. Epub 2006 Jan 3. (Pubitemid 46622047)
75. Schmidt H, Johansen JS, Gehl J, et al. Elevated serum level of YKL- 40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer. 2006;106(5):1130-1139. (Pubitemid 43297353)
76. Vergilis IJ, Szarek M, Ferrone S, et al. Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma. J Invest Dermatol. 2005;125(3):526-531.
77. Hahn S, Ugurel S, Hanschmann KM, et al. Serological response to human endogenous retrovirus K in melanoma patients correlates with survival probability. AIDS Res Hum Retroviruses. 2008;24(5):717-723. (Pubitemid 351748779)
78. Persson L, Hårdemark HG, Gustafsson J, et al. S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke. 1987;18(5):911-918. (Pubitemid 17126635)
79. Deichmann M, Benner A, Bock M, et al. S100-Beta, melanomainhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol. 1999;17(6):1891-1896. (Pubitemid 29269262)
80. Jury CS, McAllister EJ, MacKie RM. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol. 2000;143(2):269-274. (Pubitemid 30650392)
81. Acland K, Evans AV, Abraha H, et al. Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma. Br J Dermatol. 2002;146(5):832-835. (Pubitemid 34539193)
82. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3635-3648. (Pubitemid 32786276)
83. Mian S, Ugurel S, Parkinson E, et al. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol. 2005;23:5088-5093. (Pubitemid 46224016)
84. Findeisen P, Zapatka M, Peccerella T, et al. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J Clin Oncol. 2009 Mar 23. Epub ahead of print.